Reaction
Red Blood Cell Count Abnormal reporting signals
As of the last recalculation, Red Blood Cell Count Abnormal appears in 1,444 FAERS reports alongside 28 co-occurring drug terms. The strongest observed disproportionality signal is NIRAPARIB (PRR 35.0).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Niraparib | 52 | 35.0 | 35.1 |
| Ruxolitinib | 150 | 33.6 | 33.6 |
| Avapritinib | 16 | 19.2 | 19.3 |
| Eculizumab | 63 | 17.4 | 17.4 |
| Erythropoietin | 24 | 17.1 | 17.1 |
| Acalabrutinib | 14 | 16.8 | 16.8 |
| Hydroxyurea | 24 | 16.6 | 16.6 |
| Ribociclib | 35 | 16.4 | 16.4 |
| Olaparib | 19 | 13.3 | 13.3 |
| Rucaparib | 8 | 13.1 | 13.1 |
| Venetoclax | 50 | 12.1 | 12.1 |
| Inclisiran | 6 | 10.8 | 10.8 |
| Palbociclib | 68 | 10.7 | 10.7 |
| Ibrutinib | 57 | 10.5 | 10.6 |
| Fulvestrant | 23 | 10.2 | 10.2 |
| Letrozole Tablets | 26 | 7.9 | 7.9 |
| Abemaciclib | 10 | 7.3 | 7.3 |
| Bendamustine Hydrochloride | 6 | 7.2 | 7.3 |
| Peginterferon Alfa-2A | 26 | 7.0 | 7.0 |
| Nilotinib | 14 | 6.9 | 6.9 |
| Selinexor | 4 | 6.7 | 6.7 |
| Deferasirox | 12 | 6.6 | 6.6 |
| Trifluridine And Tipiracil | 4 | 5.4 | 5.4 |
| Ravulizumab | 5 | 5.3 | 5.3 |
| Ribavirin | 21 | 4.8 | 4.8 |
| Cabozantinib | 12 | 3.6 | 3.6 |
| Lenalidomide | 97 | 3.5 | 3.5 |
| Pomalidomide | 23 | 3.3 | 3.3 |